| |
Q1
|
Q2
|
Q3
|
Q4
|
Q5
|
p-trenda
|
|---|
|
Vitamin B12
|
|
Person-years
|
296,280
|
292,419
|
290,662
|
289,062
|
288,256
| |
|
Cases, n
|
80
|
72
|
82
|
87
|
106
| |
|
Model 1b
|
1.00 (reference)
|
0.93 (0.68–1.28)
|
1.00 (0.73–1.37)
|
1.00 (0.73–1.37)
|
1.13 (0.83–1.52)
|
0.31
|
|
Model 2c
|
1.00 (reference)
|
1.09 (0.79–1.51)
|
1.25 (0.91–1.72)
|
1.28 (0.93–1.76)
|
1.37 (1.00–1.86)
|
0.04
|
|
Model 3d
|
1.00 (reference)
|
1.13 (0.80–1.59)
|
1.43 (0.99–2.06)
|
1.58 (1.07–2.34)
|
1.75 (1.13–2.71)
|
0.01
|
|
3-year exclusion analysis
|
|
Cases, n
|
71
|
64
|
71
|
79
|
91
| |
|
Model 3d
|
1.00 (reference)
|
1.13 (0.79–1.63)
|
1.40 (0.95–2.06)
|
1.64 (1.08–2.48)
|
1.74 (1.09–2.78)
|
0.02
|
|
Vitamin B6
|
|
Person-years
|
296,267
|
294,533
|
291,293
|
288,886
|
285,698
| |
|
Cases, n
|
75
|
78
|
82
|
86
|
106
| |
|
Model 1b
|
1.00 (reference)
|
1.01 (0.73–1.39)
|
0.87 (0.63–1.19)
|
0.78 (0.57–1.07)
|
0.81 (0.60–1.09)
|
0.08
|
|
Model 2c
|
1.00 (reference)
|
1.24 (0.90–1.71)
|
1.16 (0.84–1.60)
|
1.08 (0.78–1.49)
|
1.08 (0.79–1.48)
|
0.98
|
|
Model 3d
|
1.00 (reference)
|
1.17 (0.83–1.64)
|
1.04 (0.72–1.48)
|
0.89 (0.61–1.30)
|
0.81 (0.53–1.24)
|
0.16
|
|
3-year exclusion analysis
|
|
Cases, n
|
65
|
70
|
73
|
75
|
93
| |
|
Model 3d
|
1.00 (reference)
|
1.22 (0.85–1.76)
|
1.09 (0.74–1.60)
|
0.94 (0.63–1.42)
|
0.89 (0.57–1.40)
|
0.36
|
|
Folate
|
|
Person-years
|
292,275
|
290,461
|
290,196
|
292,381
|
291,364
| |
|
Cases, n
|
107
|
83
|
79
|
89
|
69
| |
|
Model 1b
|
1.00 (reference)
|
0.80 (0.60–1.07)
|
0.81 (0.60–1.08)
|
0.88 (0.66–1.17)
|
0.67 (0.49–0.92)
|
0.03
|
|
Model 2c
|
1.00 (reference)
|
1.02 (0.76–1.37)
|
1.10 (0.82–1.49)
|
1.24 (0.93–1.67)
|
1.00 (0.72–1.37)
|
0.71
|
|
Model 3d
|
1.00 (reference)
|
1.01 (0.74–1.36)
|
1.10 (0.80–1.51)
|
1.27 (0.92–1.75)
|
1.07 (0.74–1.55)
|
0.50
|
|
3-year exclusion analysis
|
|
Cases, n
|
95
|
71
|
76
|
74
|
60
| |
|
Model 3d
|
1.00 (reference)
|
0.97 (0.70–1.34)
|
1.19 (0.85–1.65)
|
1.18 (0.84–1.68)
|
1.04 (0.70–1.54)
|
0.65
|
|
Methionine
|
|
Person-years
|
293,843
|
294,206
|
291,479
|
289,686
|
287,464
| |
|
Cases, n
|
107
|
92
|
53
|
74
|
101
| |
|
Model 1b
|
1.00 (reference)
|
0.98 (0.74–1.29)
|
0.51 (0.37–0.71)
|
0.60 (0.45–0.81)
|
0.69 (0.53–0.91)
|
0.001
|
|
Model 2c
|
1.00 (reference)
|
1.29 (0.97–1.72)
|
0.77 (0.55–1.09)
|
1.02 (0.74–1.40)
|
1.19 (0.88–1.60)
|
0.46
|
|
Model 3d
|
1.00 (reference)
|
1.10 (0.80–1.50)
|
0.61 (0.41–0.90)
|
0.77 (0.52–1.15)
|
0.91 (0.59–1.40)
|
0.53
|
|
3-year exclusion analysis
|
|
Cases, n
|
96
|
81
|
48
|
66
|
85
| |
|
Model 3d
|
1.00 (reference)
|
1.08 (0.77–1.51)
|
0.62 (0.41–0.93)
|
0.76 (0.50–1.15)
|
0.83 (0.53–1.31)
|
0.34
|
- a Median values of vitamin B12, vitamin B6, folate, and methionine intakes in each quintile were used to test for a linear trend across .
- b Model 1 was adjusted for age, sex, and public health center area.
- c Model 2 was adjusted for age, sex, public health center area, body mass index (quintiles), smoking (never, past, current; ≤19 cigarettes/day, 20–29 cigarettes/day, or ≥30 cigarettes/day), alcohol consumption (non-drinkers, ≤150 g/week, 150<alcohol≤300 g/week, 300<alcohol<450 g/week, or ≤450 g/week), family history of cancer, and physical activity in METs (quintiles).
- d Model 3 was model 2 that was mutually adjusted further for vitamin B12, vitamin B6, folate, and methionine
